NVCT biotech catalysts & pipeline

NUVECTIS PHARMA INC · Data as of 2026-10-25

Upcoming catalysts

NXP900 — Interim data

Late 2026

Non-small cell lung cancer (NSCLC): the clinical trial evaluating the combination of NXP900 plus osimertinib (Tagrisso™) in patients with NSCLC EGFR+ who initially responded to, and later progressed on, osimertinib, is ongoing, and we expect to provide an update by the end of this year.

Source filing

ciprocopan — FDA meeting

4Q2026

U.S. regulatory efforts underway; a pre-investigation new drug ("IND") meeting with the Food and Drug Administration ("FDA") followed by IND submission expected in 4Q2026.

Source filing

NXP200 — IND submission

4Q2026

U.S. regulatory efforts underway; IND submission expected in 4Q2026.

Source filing

NXP200 — Conference presentation

Oct 23–Oct 27

Oral presentation of additional clinical data generated by Haisco will be presented at the upcoming European Society for Medical Oncology (ESMO) conference (Madrid, Spain, October 23–27, 2026).

Source filing

Explore the free biotech catalyst calendar